There are currently 955 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama-Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Objective Health - Birmingham Gastroenterology Associates, Birmingham, Alabama
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
NCT05338697
Recruiting
VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: University of Alabama, Birmingham, Alabama
Conditions: Stroke, Stroke, Acute, Stroke, Ischemic, Stroke Hemorrhagic
Register for Updates
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
NCT05694884
Recruiting
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: ASLAN Investigative Site, Birmingham, Alabama
Conditions: Atopic Dermatitis
Register for Updates
Evaluation of the "Blue Halo Coil Catheter" for Patients With Prostatic Obstruction
NCT05714488
Recruiting
The Investigators will study a device for men in urinary retention secondary to Benign Prostatic Hyperplasia, BPH ,who are catheter dependent or who have a Post Void Residual \> 350cc. The hypothesis is that the device will allow these participants to return to volitional voiding with a Post Void Residual \<75 cc.
Gender:
MALE
Ages:
50 years and above
Trial Updated:
01/08/2024
Locations: The University of Alabama-Birmingham, Birmingham, Alabama
Conditions: Urinary Retention
Register for Updates
Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants
NCT05865041
Recruiting
The main purpose of this study is to measure the efficacy of farudodstat compared to placebo at Week 12 from the treatment start, in adult participants with Alopecia Areata (AA) with 30% or greater scalp hair loss.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/12/2023
Locations: 1 Site, Birmingham, Alabama
Conditions: Alopecia Areata
Register for Updates
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
NCT04260022
Recruiting
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (BP) or with Ph+ ALL, who have experienced resistance or intolerance to at least two tyrosine kinase inhibitors (TKIs) or in subjects with Ph+ B-cell precursor (BCP) ALL or lymphoid blast phase CML (CML LBP), who have experienced resistance or intolera... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia
Register for Updates
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
NCT03129139
Recruiting
A Phase I, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Minnelide™Capsules given daily for 21 days followed by 7 days off schedule in patients with Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/17/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer Metastatic, Colo-rectal Cancer, Solid Tumor, Solid Carcinoma, Solid Carcinoma of Stomach, Cancer of Stomach
Register for Updates
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
NCT05199285
Recruiting
This phase II trial tests whether nivolumab and ipilimumab works to shrink tumors in patients with liver cancer that has spread to nearby tissue or lymph nodes (locally advanced), has spread to other places in the body (metastatic), or cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Nivolumab and ipilim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/13/2023
Locations: University of Alabama- Birmingham, Birmingham, Alabama
Conditions: BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma
Register for Updates
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
NCT04056247
Recruiting
This study will develop an algorithm of identifying patients with stage IV NSCLC and Melanoma who could benefit from cancer treatment they receive.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/25/2023
Locations: Birmingham VAHCS, Birmingham, Alabama
Conditions: Stage IV Non-small Cell Lung Cancer, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma, Stage IV Malignant Melanoma
Register for Updates
Simple Bone Cysts in Kids
NCT02193841
Recruiting
Simple bone cysts (SBCs) are cysts filled with fluid that occur most frequently in the long bones (arms or legs) of children. There are many ways to treat SBCs but it is unclear if one is better than another. The purpose of this research trial is to compare the effectiveness of two common treatments that are used by surgeons today.
Gender:
ALL
Ages:
Between 2 years and 21 years
Trial Updated:
07/10/2023
Locations: Children's Hospital of Alabama, Birmingham, Alabama
Conditions: Bone Cyst
Register for Updates
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment
NCT03662126
Recruiting
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive ei... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/26/2023
Locations: The Kirklin Clinic of UAB Hospital, Birmingham, Alabama
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Register for Updates
Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib
NCT05280509
Recruiting
This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/16/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Myelofibrosis, Primary Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis
Register for Updates